The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen - PubMed (original) (raw)
. 1984 Dec;312(5994):513-6.
doi: 10.1038/312513a0.
- PMID: 6095109
- DOI: 10.1038/312513a0
The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen
A L Schechter et al. Nature. 1984 Dec.
Abstract
A series of rat neuro/glioblastomas all contain the same transforming gene (neu) which induces synthesis of a tumour antigen of relative molecular mass (Mr) 185,000 (p185). The neu oncogene bears homology to erb-B and the tumour antigen, p185, is serologically related to the epidermal growth factor (EGF) receptor. The two proteins, EGF receptor and p185 appear to be distinct, as they coexist in nontransformed Rat-1 cells.
Similar articles
- The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor.
Schechter AL, Hung MC, Vaidyanathan L, Weinberg RA, Yang-Feng TL, Francke U, Ullrich A, Coussens L. Schechter AL, et al. Science. 1985 Sep 6;229(4717):976-8. doi: 10.1126/science.2992090. Science. 1985. PMID: 2992090 - The neu oncogene encodes an epidermal growth factor receptor-related protein.
Bargmann CI, Hung MC, Weinberg RA. Bargmann CI, et al. Nature. 1986 Jan 16-22;319(6050):226-30. doi: 10.1038/319226a0. Nature. 1986. PMID: 3945311 - Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles.
Hung MC, Schechter AL, Chevray PY, Stern DF, Weinberg RA. Hung MC, et al. Proc Natl Acad Sci U S A. 1986 Jan;83(2):261-4. doi: 10.1073/pnas.83.2.261. Proc Natl Acad Sci U S A. 1986. PMID: 3001730 Free PMC article. - Growth factors and oncogenes in human malignant glioma.
Westermark B, Nister M, Heldin CH. Westermark B, et al. Neurol Clin. 1985 Nov;3(4):785-99. Neurol Clin. 1985. PMID: 3001490 Review. - The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies.
Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A, Greene MI. Dougall WC, et al. Oncogene. 1994 Aug;9(8):2109-23. Oncogene. 1994. PMID: 7913542 Review.
Cited by
- In Silico Exploration of Novel EGFR Kinase Mutant-Selective Inhibitors Using a Hybrid Computational Approach.
Noor MAA, Haq MM, Chowdhury MAR, Tayara H, Shim H, Chong KT. Noor MAA, et al. Pharmaceuticals (Basel). 2024 Aug 23;17(9):1107. doi: 10.3390/ph17091107. Pharmaceuticals (Basel). 2024. PMID: 39338272 Free PMC article. - Cancer treatments: Past, present, and future.
Sonkin D, Thomas A, Teicher BA. Sonkin D, et al. Cancer Genet. 2024 Aug;286-287:18-24. doi: 10.1016/j.cancergen.2024.06.002. Epub 2024 Jun 17. Cancer Genet. 2024. PMID: 38909530 Review. - YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT/mTOR and ERK/mTOR axis.
Qiao J, Feng M, Zhou W, Tan Y, Yang S, Liu Q, Wang Q, Feng W, Pan Y, Cui L. Qiao J, et al. Gastric Cancer. 2024 Jul;27(4):785-801. doi: 10.1007/s10120-024-01508-3. Epub 2024 May 23. Gastric Cancer. 2024. PMID: 38782859 Free PMC article. - The impact of nitric oxide on HER family post-translational modification and downstream signaling in cancer.
O'Neill CE, Sun K, Sundararaman S, Chang JC, Glynn SA. O'Neill CE, et al. Front Physiol. 2024 Mar 27;15:1358850. doi: 10.3389/fphys.2024.1358850. eCollection 2024. Front Physiol. 2024. PMID: 38601214 Free PMC article. Review. - Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma.
Shih CH, Lin YH, Luo HL, Sung WW. Shih CH, et al. Front Pharmacol. 2024 Mar 20;15:1326296. doi: 10.3389/fphar.2024.1326296. eCollection 2024. Front Pharmacol. 2024. PMID: 38572425 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous